Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients.

Trial Profile

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2015

At a glance

  • Drugs Interferon beta (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms SEPTIME
  • Sponsors Merck KGaA
  • Most Recent Events

    • 06 Feb 2012 Merck Serono as company and lead trial centre identified as reported by ClinicalTrials.gov.
    • 20 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top